Oral Oncology
Volume 37, Issue 7 , Pages 572-578 , October 2001

p53 codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours

Received 3 November 2000 ,Accepted 3 November 2000.

References 

  1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–194
  2. Rothman KJ, Cann CI, Flanders D, Fladers D, Fried MP. Epidemiology of laryngeal cancer. Epidemiol. Rev. 1980;2:195–209
  3. Rizos E, Sourvinos G, Spandidos DA. Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens. Oral Oncol. 1998;34:519–523
  4. Rizos E, Sourvinos G, Arvanitis DA, Velegrakis G, Spandidos DA. Low incidence of H-, K- and N-ras oncogene mutations in cytological specimens of laryngeal tumours. Oral Oncol. 1999;35:561–563
  5. Kahn T, Schwarz E, zur Hausen H. Molecular cloning and characterization of the DNA of a new human papillomavirus (HPV 30) from a laryngeal carcinoma. Int J Cancer. 1986;37:61–65
  6. Garcia-Milian R, Hernandez H, Panade L, Rodriguez C, Gonzalez N, Valenzuela C, et al.  Detection and typing of human papillomavirus DNA in benign and malignant tumours of laryngeal epithelium. Acta Otolaryngol. 1998;118:754–758
  7. Almadori G, Cadoni G, Cattani P, Posteraro P, Scarano E, Ottaviani F, et al.  Detection of human papillomavirus DNA in laryngeal squamous cell carcinoma by polymerase chain reaction. Eur J Cancer. 1996;32A:783–788
  8. Lindeberg H, Krogdahl A. Laryngeal dysplasia and the human papillomavirus. Clin Otolaryngol. 1997;22:382–386
  9. Lindeberg H, Krogdahl A. Laryngeal cancer and human papillomavirus (HPV is absent in the majority of laryngeal carcinomas). Cancer Lett. 1999;146:9–13
  10. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991;10:4129–4135
  11. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol. 1993;13:4918–4927
  12. Chomchai JS, Du W, Sarkar FH, Li YW, Jacobs JR, Ensley JF, et al.  Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope. 1999;109:455–459
  13. Salam M, Rockett J, Morris A. The prevalence of different human papillomavirus types and p53 mutations in laryngeal carcinomas (is there a reciprocal relationship?). Eur J Surg Oncol. 1995;21:290–296
  14. Anwar K, Nakakuki K, Imai H, Naiki H, Inuzuka M. Over-expression of p53 protein in human laryngeal carcinoma. Int J Cancer. 1993;53:952–956
  15. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis. 1996;17:261–264
  16. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234
  17. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530–531
  18. Hayes VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet. 1998;352:1756
  19. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF, Herrero R, Bratti MC, et al.  p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–532
  20. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO. Gyllensten UB. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531
  21. Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet. 1998;352:1631
  22. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 1998;58:4585–4586
  23. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998;352:871–872
  24. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999;354:218–219
  25. Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun. 2000;3:111–114
  26. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, et al.  p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res. 2000;60:2753–2755
  27. Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer. 2000;82:757–759
  28. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226–230
  29. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients (association with lung cancer susceptibility and prognosis). Clin Cancer Res. 1999;5:129–134
  30. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 2000;3:389–392
  31. Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5:405–409
  32. Kiaris H, Jones AS, Spandidos DA, Vaughan ED, Field JK. Loss of heterozygosity on chromosome 8 in squamous cell carcinomas of the head and neck. Int J Oncol. 1994;5:1243–1248
  33. Snijders PJ, van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990;71:173–181
  34. Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC. HPV in full thickness cervical biopsies (high prevalence in CIN 2 and CIN 3 detected by a sensitive PCR method). J Pathol. 1991;165:301–309
  35. Szyfter K, Szmeja Z, Szyfter W, Hemminki K, Banaszewski J, Jaskula-Sztul R, et al.  Molecular and cellular alterations in tobacco smoke-associated larynx cancer. Mutat Res. 1999;445:259–274
  36. Giannoudis A, Graham DA, Southern SA, Herrington CS. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer. 1999;83:66–69
  37. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, et al.  Is p53 polymorphism maintained by natural selection?. Hum Hered. 1994;44:266–270
  38. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, et al.  Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis. 1994;15:583–587
  39. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–1089
  40. Dokianakis DN, Sourvinos G, Sakkas S, Athanasiadou E, Spandidos DA. Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep. 1998;5:1195–1198
  41. Dokianakis DN, Papaefthimiou M, Tsiveleka A, Spandidos DA. High prevalence of HPV18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears. Oncol Rep. 1999;6:1327–1331

PII: S1368-8375(00)00139-1

Oral Oncology
Volume 37, Issue 7 , Pages 572-578 , October 2001

Article Tools

* Image Usage & Resolution